Cover image of The Bio Report
(20)
Business
Investing

The Bio Report

Updated 5 days ago

Business
Investing
Read more

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Read more

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

iTunes Ratings

20 Ratings
Average Ratings
10
4
3
1
2

Sound quality lacking, but great content

By DGrande - Sep 07 2018
Read more
Can’t understand why this isn’t more popular...it’s incredibly relevant, instructive, and brings in great guests. These are the things I need to know for my team and company. 5 stars.

Good content

By Inrater - Sep 06 2018
Read more
I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.

iTunes Ratings

20 Ratings
Average Ratings
10
4
3
1
2

Sound quality lacking, but great content

By DGrande - Sep 07 2018
Read more
Can’t understand why this isn’t more popular...it’s incredibly relevant, instructive, and brings in great guests. These are the things I need to know for my team and company. 5 stars.

Good content

By Inrater - Sep 06 2018
Read more
I am a longtime investor in Biotech and find the topics and interviews extremely interesting. The sound is not that good but it really doesn’t matter when the content is interesting. I would shorten the intro jingle by 50%. Keep up the good work.
Cover image of The Bio Report

The Bio Report

Latest release on Feb 20, 2020

The Best Episodes Ranked Using User Listens

Updated by OwlTail 5 days ago

Rank #1: Jimmy Carter's Final Wish: Eradicating Guinea Worm

Podcast cover
Read more
President Jimmy Carter, at a recent press conference discussing his cancer diagnosis and treatment, expressed his wish to outlive the last Guinea worm. The Carter Center, since 1986, has led a global effort to eradicate Guinea worm disease with great success and its goal is within reach. We spoke to Ernesto Ruiz-Tiben, director of The Carter Center’s Guinea Worm Eradication Program, about its efforts, the history behind it, and what lessons can be drawn in combating other public health threats throughout the world.

Aug 27 2015

19mins

Play

Rank #2: Biotech Industry Moves Towards a Patent Cliff

Podcast cover
Read more
Scrutiny of drug prices around the globe is expected to exert growing pressure on the biopharmaceutical sector. EvaluatePharma, in its recently issued World Preview 2017, Outlook to 2022 says that despite consensus forecasts for worldwide drug sales hitting more than $1 trillion in 2022, it does reflect a drop from the same period last year. We spoke to Antonio Iervolino, head of forecasting for evaluate pharma, about the new report, the outlook for the sector and the potential for a new patent cliff with the advent of biosimilars.

Jul 13 2017

14mins

Play

Rank #3: Should Investors Temper Their Enthusiasm for CAR-T Therapies

Podcast cover
Read more
CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valuations of CAR-T companies should be tempered by an eye towards the risks. We spoke to Jacob Plieth, report author and senior reporter for EP Vantage, about the promise of these therapies, what we know about their safety and efficacy, and why the muddy intellectual property landscape is a concern.

Feb 05 2015

24mins

Play

Rank #4: CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries

Podcast cover
Read more
For many patients with rare and difficult to diagnose conditions, it can take many years and many doctors to find a correct answer. CrowdMed is trying to offering an alternative to patients by allowing them to tap the wisdom of crowds and letting medical detectives who sign on to the site try to find the right answer. We spoke to Jared Heyman, founder and CEO of CrowdMed, about the problem with the traditional way doctors diagnose patients, the wisdom of crowds, and the case for making medicine a team sport.

Jul 09 2015

19mins

Play

Rank #5: ALS Fight Carries Muller from Patient to Biotech CEO

Podcast cover
Read more
Bernard Muller was a successful businessman in the maritime and oil industry, but when he was diagnosed with the neurodegenerative disease ALS in 2010, he turned his entrepreneurial skills toward developing new therapies to treat the disease. Muller co-founded the world’s largest genetic research project for ALS, project MinE, and launched Treeway, a biotech company developing new therapies for ALS. As the Biotechnology Industry Organization kicks off its BIO 2015 International Convention in Philadelphia June 15, Muller is a finalist as one of the organization’s Everyday Superheroes in the pharma/biotech category. We spoke to Muller about his decision to launch Treeway, the active role he sees for patients, and why he thinks traditional approaches to drug development and clinical trial design have not served ALS patients well.

Jun 11 2015

17mins

Play

Rank #6: What a Decade of Investment Tells Us about the Health of Biotech

Podcast cover
Read more
A detailed view of funding of emerging therapeutic companies over the past ten years shows despite a rebound in venture financing, companies continue to struggle to find early-stage money. Nevertheless, the report shows the overall health of investment in the sector is thriving. We spoke to Dave Thomas, senior director of industry research and analysis for the Biotechnology Industry Organization and co-author of the report, about BIO’s findings, what therapeutic areas attracted the most financing, and what impact the capital markets have had on partnering and licensing activity.

Jun 25 2015

14mins

Play

Rank #7: The Year in Biotech and What to Watch in 2019

Podcast cover
Read more
As the year draws to a close, we continue what’s become an annual tradition and look back on the year in biotech and ahead to the J.P. Morgan Healthcare Conference and beyond with Adam Feuerstein, senior biotech writer for STAT News. Adam tries to make sense of a puzzling year for biotech that seemed full of contradictions, offers some thoughts on the highs and lows of the past 12 months, and discusses what he’ll be watching for during the J.P. Morgan Healthcare Conference.

Dec 27 2018

25mins

Play

Rank #8: The Outlook for Biotech in 2018

Podcast cover
Read more
We conclude our biotech review-preview series with our final installment this week as we take a look at the year ahead as the industry readies for the JPMorgan Healthcare Conference. We spoke to Jon Gardner, U.S. News Editor for EP Vantage, about the EP Vantage 2018 Preview(http://bit.ly/2CT2RDP), the outlook for big-value drug launches, and whether dealmaking or clinical success will drive stock prices in 2018. As a note, this podcast was recorded prior to Spark Therapeutics announcement of its pricing for its gene therapy Luxturna.

Jan 04 2018

19mins

Play

Rank #9: Why Biomarkers May Be the Key to Immuno-Oncology Success

Podcast cover
Read more
Developers of cancer immunotherapies are in a race to find combinations that can distinguish their products for specific indications. Biomarkers, which have played an essential role in the development of targeted therapies, have proven a much more complex challenge in the realm of immuno-oncology. Nevertheless, biomarkers may be the key to winning the competitive battles in immuno-oncology. We spoke to Rachel Laing, managing partner of Bionest Partners, about the role for biomarkers in immuno-oncology, why immuno-oncology companies have much at stake in the hunt for biomarkers that can better select patients for their therapies, and the role biomarkers will play in the move toward real-time oncology.

May 10 2018

26mins

Play

Rank #10: Why Foresite Capital is Betting Big on the Convergence of AI and Biotech

Podcast cover
Read more
The convergence of artificial intelligence and the life sciences is promising to revolutionize the entire healthcare continuum including the way drugs are discovered, how clinical trials are conducted, the methods physicians use to diagnose patients, and how patients are monitored and treated. The life sciences investment firm Foresite Capital, armed with a new $668 million fund, is helping to bring about this change by backing innovative companies working at this nexus information technology and biotechnology. We spoke to Brett Zbar and Vik Bajaj, managing directors of Foresite, about their new fund, what constitutes a Foresite investment, and why they believe this is not just the latest fad, but a meaningful change in the way life sciences companies seek to address the challenges in all aspects of healthcare.

Aug 23 2018

28mins

Play

Rank #11: California, Aid-in-Dying, and What We've Learned from Oregon

Podcast cover
Read more
The California legislature earlier this month passed a bill that would allow physicians to aid terminally ill patients who wanted to end their lives. California would become the fifth state to enact such legislation. We spoke to David Grube, national medical director of Compassion & Choices, a nonprofit working to expand end of life options, about the legislation, how attitudes among the public and physicians have changed, and what we’ve learned since Oregon passed the first such law 17 years ago.

Sep 17 2015

18mins

Play

Rank #12: Targeting the Regulators of Genes to Treat Disease

Podcast cover
Read more
While most drug developers have sought to target aberrant genes or the proteins driving diseases, Syros Pharmaceuticals has developed a proprietary platform that targets the regulatory region of DNA to not only turn genes on or off but modulate their activity as well. The company is initially focusing on cancer and monogenic diseases. We spoke to Nancy Simonian, CEO of Syros, about the company’s platform technology, the opportunities in targeting regulators of genes, and why this could represent a broad new approach to treating diseases.

Apr 06 2018

20mins

Play

Rank #13: Designing Small-Molecule, Immuno-Oncology Drugs That Act Like Biologics

Podcast cover
Read more
Kleo Pharmaceuticals is a developing next-generation immuno-oncology drugs that are small-molecule compounds designed to act like biologics. Kleo’s compounds activate patients’ immune systems to target and destroy cancer cells but are faster and less costly to design and produce than biologics. We spoke to Doug Manion, CEO of Kleo, about the company’s platform technology, why he thinks it will produce safer and more effective immunotherapies, and the potential to use these compounds in conjunction with existing biologics to enhance their activity.

Feb 14 2019

23mins

Play

Rank #14: Home-Brew Morphine, Dual Use Technology, and the Biologist's Repsonsibilities

Podcast cover
Read more
A recent article in Nature Chemical Biology that shows it is possible to convert sugar into morphine with genetically engineered yeast has sparked public attention over the potential illicit use of the technology and the need for regulation. The work, though, also opens up significant possibilities for producing a wide range of drugs and the discovery of new ones to treat everything from cancer to infectious diseases. We spoke John Dueber, assistant professor of bioengineering at the University of California, Berkeley and one of the authors of the study, about the work, its implications, and what role biologists need to play in regulating themselves.

May 20 2015

20mins

Play

Rank #15: Using Real-World Evidence to Improve Drug Development

Podcast cover
Read more
The availability of a growing body of real-world evidence has regulators considering how clinical trials using disparate sources of data might work. Many see harnessing such information as a way to provide better insight into the safety and efficacy of drugs while reducing the cost of clinical trials. A number of issues, though, will need to be addresses as the U.S. Food and Drug Administration takes a first pass at a framework for using real-world evidence. We spoke Nancy Dreyer, chief scientific officer & senior vice president of real-world & analytic solutions for IQVIA, about real-world data, its potential to change the way clinical trials are conducted, and the challenges to applying it.

Oct 11 2018

26mins

Play

Rank #16: Carrying Therapeutic Payloads Across the Blood-Brain Barrier

Podcast cover
Read more
The blood-brain barrier provides essential protection against pathogens while allowing needed oxygen and nutrients to pass. However, one challenge it presents is getting therapeutics delivered to the brain and central nervous system. Bioasis Technologies has developed a way to attach fusion proteins to drugs to allow them to pass the blood-brain barrier. We spoke to Mark Day, CEO of Bioasis, about its platform technology, what is known about it from testing to date, and the potential therapeutic implications of being able to deliver drugs systemically that can reach the central nervous system and brain.

Jul 12 2018

24mins

Play

Rank #17: Regeneron Embraces Genetics as Fundamental to Drug Development

Podcast cover
Read more
Drug discovery and development is a slow and costly process, but the Regeneron Genetics Center represents a drugmakers’ bet that harnessing large amounts of genetic data can point the way to better targets, greater success rates, and ultimately better drugs. We spoke to Aris Baras, vice president and head of the Regeneron Genetics Center ahead of the Precision Medicine World Conference 2017 in Silicon Valley about how large genetic studies are brining fundamental change to the drug development process, the approach Regeneron is taking, and why its becoming a necessary element of drug development today.

Jan 19 2017

32mins

Play

Rank #18: Agenus Advances Broad Immuno-Oncology Pipeline

Podcast cover
Read more
Agenus is an immuno-oncology company with a long history and a broad portfolio. To help fund its pipeline, it entered into a significant alliance with Gilead Sciences in December 2018 and has used an unusual funding mechanism by raising money through what it described as the first asset-backed digital-security offering. We spoke to John Castle, head of translational medicine and bioinformatics at Agenus, about the company’s approach to managing and prioritizing its pipeline, its use of artificial intelligence, and the recent deals it’’s done to fund development.

Apr 11 2019

27mins

Play

Rank #19: Technology Allows Drugmakers to Tag and Authenticate Individual Pills

Podcast cover
Read more
The problem of counterfeit and falsified medicines is not just an economic problem for the pharmaceutical industry, but also a threat to public health. TruTag Technologies is seeking to address the problem with its nano-scale technology that allows drugmakers to encode information on individual doses of medication to authenticate a drug and provide details on its origin and intended market. We spoke to Barry McDonough, senior vice president of business development for TruTag, about the technology, how it works, and how it can address a global health concern.

Jul 27 2017

20mins

Play

Rank #20: Why Drug Companies May Soon Become Health Technology Companies

Podcast cover
Read more
The convergence of technology and life sciences, changing consumer behavior, and increasing pricing pressures on drug and device makers are forcing these companies to rethink business models and how they derive value from their products, according to a new EY Progressions 2018 report. The report argues that life sciences companies will no longer be able to rely exclusively on product-centric innovations, which face diminishing returns as health systems wrestle with cost constraints. We spoke to Pamela Spence, EY global life sciences industry leader, about the report, what a growing trend in collaborations between technology and healthcare companies may say about where the industry is heading, and why the future of life sciences companies may be as health technology companies.

Mar 15 2018

24mins

Play